APLS vs BMRN · rev $1.00B vs P/E 40, rev $1.76B
Apellis Pharmaceuticals Inc (APLS) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
APLS currently screens at market cap $2.29B. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the APLS and BMRN stock pages for the full models.
Not investment advice.